In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Amgen, with a price target of $300.00. The company’s shares closed last Friday at $295.27. Schott covers the ...

New York State Common Retirement Fund trimmed its Regeneron stake by 5% in Q1, selling over 6,800 shares worth millions.

Major indices were in the green earlier on Wednesday as traders digested more bank earnings and another key inflation report.

Major indices closed higher on Monday as traders continued to monitor trade headlines ahead of key inflation data and the ...

The results position Hengrui to seek approval of the Zepbound-like drug in China and Kailera, a well-funded biotech startup, ...

Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...

Read about Regeneron Pharmaceuticals Inc (REGN:XNAS) stock and today's latest news and financial updates.